Brief: Xbrane Biopharma: Update On Ranibizumab Biosimilar Candidate FDA Filing
04/07/2022 07:33
July 4 (Reuters) - Xbrane Biopharma AB XBRANE.ST :
* RECEIVED GENERAL ADVICE LETTER WITH RECOMMENDATIONS FOR
RESUBMISSION OF BLA FOR INVESTIGATIONAL BIOSIMILAR CANDIDATE TO
LUCENTIS
* BASED ON ADVICE RECEIVED XBRANE PLANS TO RESUBMIT BLA
DURING
2022
Source text for Eikon: ID:nMFNBXJ7z
Further company coverage: XBRANE.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))